A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors

Growth Factor ◽

Tyrosine Kinases ◽

Phase I Study ◽

Growth Factor Receptor ◽

Selective Inhibitor ◽

Chinese Patients ◽

Vascular Endothelial ◽

Advanced Solid Tumors ◽

137 A phase I study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients with advanced solid tumors

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(04)80145-9 ◽

2004 ◽

Vol 2 (8) ◽

pp. 44 ◽

Cited By ~ 6

Author(s):

A. Tolcher ◽

J.J. O'Leary ◽

J. DeBono ◽

K. Molpus ◽

C. Woodard ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Tyrosine Kinase Inhibitor ◽

Phase I Study ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Advanced Solid Tumors ◽

Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors

Annals of Oncology ◽

10.1093/annonc/mdv144 ◽

2015 ◽

Vol 26 (6) ◽

pp. 1230-1237 ◽

Cited By ~ 42

Author(s):

E.G. Chiorean ◽

H.I. Hurwitz ◽

R.B. Cohen ◽

J.D. Schwartz ◽

R.P. Dalal ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Advanced Solid Tumors ◽

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-08-0652 ◽

2008 ◽

Vol 14 (22) ◽

pp. 7272-7283 ◽

Cited By ~ 389

Author(s):

Dana D. Hu-Lowe ◽

Helen Y. Zou ◽

Maren L. Grazzini ◽

Max E. Hallin ◽

Grant R. Wickman ◽

...

Keyword(s):

Growth Factor ◽

Tyrosine Kinases ◽

Receptor Tyrosine Kinases ◽

Growth Factor Receptor ◽

Selective Inhibitor ◽

Vascular Endothelial ◽

Antitumor Activities ◽

Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors

Cancer Science ◽

10.1111/cas.12014 ◽

2012 ◽

Vol 103 (12) ◽

pp. 2135-2138 ◽

Cited By ~ 11

Author(s):

Isamu Okamoto ◽

Tokuzo Arao ◽

Masaki Miyazaki ◽

Taroh Satoh ◽

Kunio Okamoto ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Phase I Study ◽

Peptide Vaccine ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Advanced Solid Tumors ◽

Clinical Phase ◽

KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties

Urologic Oncology Seminars and Original Investigations ◽

10.1016/j.urolonc.2007.03.023 ◽

2007 ◽

Vol 25 (4) ◽

pp. 359-360

Author(s):

Gregory Metzger

Keyword(s):

Growth Factor ◽

Tyrosine Kinases ◽

Receptor Tyrosine Kinases ◽

Potent Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Antitumor Activities ◽

SKLB610: A Novel Potential Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases Inhibits Angiogenesis and Tumor Growth in Vivo

Cellular Physiology and Biochemistry ◽

10.1159/000329978 ◽

2011 ◽

Vol 27 (5) ◽

pp. 565-574 ◽

Cited By ~ 12

Author(s):

Zhi-Xing Cao ◽

Ren-Lin Zheng ◽

Hong-Jun Lin ◽

Shi-Dong Luo ◽

Yan Zhou ◽

...

Keyword(s):

Growth Factor ◽

Tumor Growth ◽

Tyrosine Kinases ◽

Receptor Tyrosine Kinases ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Potential Inhibitor ◽

Expression of cyclooxygenase-2, vascular endothelial growth factor, and epidermal growth factor receptor in Chinese patients with esophageal squamous cell carcinoma

Journal of Cancer Research and Therapeutics ◽

10.4103/0973-1482.163838 ◽

2015 ◽

Vol 11 (5) ◽

pp. 44 ◽

Cited By ~ 2

Author(s):

Chang Dong ◽

Bing-Qun Wu ◽

Xin-Chun Duan ◽

Guan Shi ◽

Min Gong ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Esophageal Squamous Cell Carcinoma ◽

Growth Factor Receptor ◽

Chinese Patients ◽

Vascular Endothelial ◽

Epidermal Growth ◽

Phase I study of epidermal growth factor receptor (EGFR) inhibitor, erlotinib, and vascular endothelial growth factor monoclonal antibody, bevacizumab, in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.5539 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 5539-5539 ◽

Cited By ~ 9

Author(s):

A. M. Mauer ◽

E. E. W. Cohen ◽

S. J. Wong ◽

M. Kozloff ◽

J. Winegarden ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Phase I Study ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Egfr Inhibitor ◽

Metastatic Squamous Cell Carcinoma ◽

Epidermal Growth ◽

Anti-angiogenic and anti-tumor effects of TAK-593, a potent and selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor tyrosine kinase

Cancer Science ◽

10.1111/cas.12101 ◽

2013 ◽

Vol 104 (4) ◽

pp. 486-494 ◽

Cited By ~ 9

Author(s):

Yoshiko Awazu ◽

Akio Mizutani ◽

Yoshinori Nagase ◽

Shuntarou Tsuchiya ◽

Kazuhide Nakamura ◽

...

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Receptor Tyrosine Kinase ◽

Growth Factor Receptor ◽

Selective Inhibitor ◽

Platelet Derived Growth Factor ◽

Vascular Endothelial ◽

Synthesis and Structure−Activity Relationships of Soluble 7-Substituted 3-(3,5-Dimethoxyphenyl)-1,6-naphthyridin-2-amines and Related Ureas as Dual Inhibitors of the Fibroblast Growth Factor Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinases

Journal of Medicinal Chemistry ◽

10.1021/jm0500931 ◽

2005 ◽

Vol 48 (14) ◽

pp. 4628-4653 ◽

Cited By ~ 35

Author(s):

Andrew M. Thompson ◽

Amy M. Delaney ◽

James M. Hamby ◽

Mel C. Schroeder ◽

Teresa A. Spoon ◽

...

Keyword(s):

Growth Factor ◽

Tyrosine Kinases ◽

Fibroblast Growth Factor Receptor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Fibroblast Growth ◽

Structure Activity ◽

Dual Inhibitors ◽